Side Effects of toremifene: A Synthesis of Findings from 26 Studies
- Home
- Side Effects of toremifene
This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Side Effects of toremifene: A Synthesis of Findings from 26 Studies", please consult your doctor.
For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
Major Research Findings
Toremifene is an antiestrogen drug used to treat metastatic breast cancer in postmenopausal women. Toremifene has been shown to have beneficial effects on bone and blood lipids, similar to tamoxifen. 21 . However, toremifene, like tamoxifen, may increase the risk of endometrial cancer. 21 . Toremifene may also cause memory impairment. 16 . Additionally, toremifene may cause abnormal cell division in the liver. 24 .
Reasons for Side Effects
The side effects of toremifene may be caused by its binding to estrogen receptors and its metabolism in the liver. Toremifene can bind to estrogen receptors and exert estrogen-like effects, which may increase the risk of endometrial cancer. 21 . Toremifene is metabolized in the liver to produce active metabolites. These metabolites may damage DNA, leading to memory impairment and abnormal cell division in the liver. 16 , 24 .
Common Side Effects
Endometrial Cancer
Toremifene, similar to tamoxifen, may increase the risk of endometrial cancer. 21 .
Memory Impairment
Toremifene may cause memory impairment. 16 .
Abnormal Cell Division in the Liver
Toremifene may cause abnormal cell division in the liver. 24 .
Side Effect Management
Endometrial Cancer Management
Regular endometrial exams are recommended to reduce the risk of endometrial cancer. 21 .
Memory Impairment Management
Lifestyle changes and cognitive training are recommended to maintain cognitive function and prevent memory impairment while using toremifene. 16 .
Abnormal Cell Division in the Liver Management
Regular liver function tests are recommended to prevent abnormal cell division in the liver. 24 .
Comparison Between Studies
Commonalities
Multiple studies have shown that toremifene, similar to tamoxifen, has beneficial effects on bone and blood lipids. 21 , 9 . Several studies suggest that toremifene may increase the risk of endometrial cancer. 21 , 25 .
Differences
Some studies suggest that toremifene is less effective than tamoxifen in treating breast cancer. 15 . Other studies indicate that toremifene may have fewer side effects than tamoxifen. 1 .
Real-Life Application Considerations
Toremifene should be used only under the guidance of a doctor as a treatment for metastatic breast cancer in postmenopausal women. When using toremifene, it is crucial to consider the risks of endometrial cancer, memory impairment, and abnormal cell division in the liver. 21 , 16 , 24 . Regular checkups are essential while using toremifene.
Limitations of Current Research
Research on toremifene side effects is still inadequate, particularly regarding long-term side effects. 6 . Side effects of toremifene can vary from person to person. 1 . Therefore, it is difficult to predict all side effects of toremifene.
Future Research Directions
Long-term follow-up studies are needed to determine the long-term side effects of toremifene. 6 . Research is also needed to predict toremifene side effects on an individual basis. 1 .
Conclusion
Toremifene is an effective drug for treating metastatic breast cancer in postmenopausal women, but it carries risks such as endometrial cancer, memory impairment, and abnormal cell division in the liver. 21 , 16 , 24 . When using toremifene, it is important to consider these risks and discuss with your doctor to choose the right treatment.
Benefit Keywords
Risk Keywords
Article Type
Author: ZhouWeihang, JiangYiwei, XuYaqian, WangYaohui, MaXiaowei, ZhouLiheng, LinYanping, WangYan, WuZiping, LiMin, YinWenjin, LuJinsong
Language : English
Author: HongJin, HuangJiahui, ShenLili, ZhuSiji, GaoWeiqi, WuJiayi, HuangOu, HeJianrong, ZhuLi, ChenWeiguo, LiYafen, ChenXiaosong, ShenKunwei
Language : English
Author: AhmadiHamed, DaneshmandSiamak
Language : English
Author: AhmadiHamed, DaneshmandSiamak
Language : English
Author: KimHoward S, FreedlandStephen J
Language : English
Author: MukherjeeSayan, MajumderDurjoy
Language : English
Author: MurakamiShigeki, YamamotoYasuhisa
Language : Japanese
Author: Diez-PerezAdolfo
Language : English
Language : English
Author: HamedH, KotheriA, Beechey-NewmanN, FentimanI S
Language : English
Author: MoriiHirotoshi
Language : Japanese
Author: MäenpääHanna, SaransaariPirjo, TähtiHanna
Language : English
Author: LiuXuemei, PishaEmily, TonettiDebra A, YaoDan, LiYan, YaoJiaqin, BurdetteJoanna E, BoltonJudy L
Language : English
Author: LehenkariPetri, ParikkaVilhelmiina, RautialaTimo J, WeckströmMatti, DahllundJohanna, HärkönenPirkko L, VäänänenH Kalervo
Language : English
Author: NagykálnaiTamás
Language : Hungarian
Author: ChenDuo, WuChun Fu, ShiBin, XuYong Meng
Language : English
Author: DoiT, NishiyamaK, WakasugiJ, OotakiS, KikuchiM, KubotaK, YamamotoH
Language : Japanese
Author: InoueK, TabeiT, KusawakeT, SugamataN, SuemasuK, HigashiY, KurosumiM
Language : Japanese
Author: BoströmA, Sjölin-ForsbergG, WilkingN, BerghJ
Language : English
Author: Yao, Jordan
Language : English
Antiestrogen stimulated human endometrial cancer growth: laboratory and clinical considerations.
Author: TonettiD A, O'ReganR, TanjoreS, EnglandG, JordanV C
Language : English
Author: HolliK
Language : English
Author: SoeL, WurzG T, MäenpääJ U, HubbardG B, CadmanT B, WiebeV J, TheonA P, DeGregorioM W
Language : English
Author: SargentL M, DraganY P, SattlerC, BahnubN, SattlerG, MartinP, CisnerosA, MannJ, ThorgeirssonS, JordanV C, PitotH C
Language : English
Author: JordanV C
Language : English
High dose toremifene in advanced breast cancer resistant to or relapsed during tamoxifen treatment.
Author: PyrhönenS, ValavaaraR, VuorinenJ, HajbaA
Language : English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.